TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up ...

Diabetes affects millions worldwide, often triggering complications such as insulin resistance and fatty liver disease. To ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

Anyone who has tried to lose weight by cutting calories knows the frustration—after initial success, weight loss slows down ...

Biomedical engineer Joshua Doloff uses federal funding to pioneer immunotherapies that could free diabetes patients from ...

Delirium is a serious condition that causes confusion and disorientation. It can come on suddenly and may be triggered by ...

ATTD conference, experts debated whether patients who use continuous glucose monitoring should aim for normal glycemia.

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

Amy Schumer endorses the new weight loss drug Mounjaro, praising its effectiveness after an adverse experience with Wegovy.

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...